Reversal of fragile X phenotypes by manipulation of AβPP/Aβ levels in Fmr1KO mice
about
Dysregulation and restoration of translational homeostasis in fragile X syndromeEmerging pharmacologic treatment options for fragile X syndromeLearning and behavioral deficits associated with the absence of the fragile X mental retardation protein: what a fly and mouse model can teach us.The pathophysiology of fragile X (and what it teaches us about synapses)Targeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromesAlzheimer-related decrease in CYFIP2 links amyloid production to tau hyperphosphorylation and memory loss.Therapeutic Strategies in Fragile X Syndrome: From Bench to Bedside and BackGenetic manipulation of STEP reverses behavioral abnormalities in a fragile X syndrome mouse model.Pax6-dependent cortical glutamatergic neuronal differentiation regulates autism-like behavior in prenatally valproic acid-exposed rat offspringFrom FMRP function to potential therapies for fragile X syndrome.Antipurinergic therapy corrects the autism-like features in the Fragile X (Fmr1 knockout) mouse model.Soy-based diet exacerbates seizures in mouse models of neurological diseaseMetabotropic glutamate receptor 5 knockout reduces cognitive impairment and pathogenesis in a mouse model of Alzheimer's disease.Fluorescent labeling of dendritic spines in cell cultures with the carbocyanine dye "DiI".A hypothesis regarding the molecular mechanism underlying dietary soy-induced effects on seizure propensityAbnormal intracellular accumulation and extracellular Aβ deposition in idiopathic and Dup15q11.2-q13 autism spectrum disordersIncreasing our understanding of human cognition through the study of Fragile X Syndrome.Fragile X mental retardation protein expression in Alzheimer's diseaseImpact of acamprosate on plasma amyloid-β precursor protein in youth: a pilot analysis in fragile X syndrome-associated and idiopathic autism spectrum disorder suggests a pharmacodynamic protein marker.Identification of fragile X syndrome specific molecular markers in human fibroblasts: a useful model to test the efficacy of therapeutic drugs.Neuronal nucleus and cytoplasm volume deficit in children with autism and volume increase in adolescents and adults.Fragile X mental retardation protein: from autism to neurodegenerative disease.Long-term Continuous EEG Monitoring in Small Rodent Models of Human Disease Using the Epoch Wireless Transmitter System.The regulation of AβPP expression by RNA-binding proteinsTransgene expression in the Nop-tTA driver line is not inherently restricted to the entorhinal cortex.Persistent astrocyte activation in the fragile X mouse cerebellumFragile X syndrome: causes, diagnosis, mechanisms, and therapeutics.Finding novel distinctions between the sAPPα-mediated anabolic biochemical pathways in Autism Spectrum Disorder and Fragile X Syndrome plasma and brain tissueImpairment of fragile X mental retardation protein-metabotropic glutamate receptor 5 signaling and its downstream cognates ras-related C3 botulinum toxin substrate 1, amyloid beta A4 precursor protein, striatal-enriched protein tyrosine phosphatase,Multiple Drug Treatments That Increase cAMP Signaling Restore Long-Term Memory and Aberrant Signaling in Fragile X Syndrome Models.Astrocyte-secreted thrombospondin-1 modulates synapse and spine defects in the fragile X mouse model.Outcome measures for clinical trials in fragile X syndrome.APP Causes Hyperexcitability in Fragile X Mice.Impaired activity-dependent neural circuit assembly and refinement in autism spectrum disorder genetic models.Commentary: Depletion of the Fragile X Mental Retardation Protein in Embryonic Stem Cells Alters the Kinetics of Neurogenesis.Early-Onset Network Hyperexcitability in Presymptomatic Alzheimer's Disease Transgenic Mice Is Suppressed by Passive Immunization with Anti-Human APP/Aβ Antibody and by mGluR5 Blockade.What's hAPPening at synapses? The role of amyloid β-protein precursor and β-amyloid in neurological disorders.A common STEP in the synaptic pathology of diverse neuropsychiatric disorders.Fragile X mental retardation protein and synaptic plasticityProgress toward treatments for synaptic defects in autism.
P2860
Q26782616-3B2CE6C7-D4C5-4137-BA0A-902605497543Q26829152-CE53E4F4-21BC-4216-B98E-9063D45F5F76Q26866506-DDC5D9FA-13A4-4CB7-8324-9A368D286997Q27010675-E3758914-939C-4004-8588-F9394B3258DDQ27023257-4ABA4F03-A299-4480-AFAD-8A3AB04E20B8Q27303472-EFA4E62B-5941-4FEE-8A60-39B7E6952622Q27337360-36C3962C-0516-423E-B5DE-DDF6858BCCCAQ28261563-DC2E09D5-EC5E-4437-8DDF-1A58B3270950Q28941206-571ECDD5-8CEF-406E-B68F-38D9A481CF6BQ30410502-A3A69ED6-E6BE-447B-A2A1-308AACDC4641Q30418368-B631EF2B-574F-452D-8EF5-204E4828BB59Q30445118-43382359-E1C5-417F-885C-D1539ED2859EQ30580280-CF1C8706-9AC1-4DFE-ADD6-2FCBEDFE12A8Q33620157-14C957DE-FB99-4687-83B0-A37E2F81614FQ34125778-BCA6B5F8-0BBC-4105-B04A-668232A50247Q34261556-61E87CF6-AB42-4688-B5FA-B1866970908EQ34435526-0084B38B-15EA-41E4-9239-48B2D84C6898Q34521866-36A54F99-4D8E-494E-B5C4-15D52044FC48Q34620558-374791E6-2A76-42A2-9F4D-0A9A640AEFACQ34871401-7438376B-63E9-4B96-A555-C58D4FB6EDC1Q34998124-A4FD626F-1D66-4C6E-B128-1022B9B7B731Q35077291-99532846-09AC-454B-BABF-BBD795230F9DQ35980653-45EEE490-6836-473E-9461-1AD5012B180BQ36110142-187EFC9A-FA07-4CFB-B066-9A6069F9A68BQ36161795-277E5515-5BFB-433D-A80E-33DD82D60A14Q36186534-74C87B1A-6EB4-4967-9EA0-5C7A3EB90D9CQ36498006-E0674798-B9BD-4716-9B58-73BBDE07E8D5Q36925690-70451669-7C9C-4F2B-B1F2-81A532EF77BAQ36985727-8F82DB2A-F7D7-46F2-B5AB-9CB6E301EAADQ37054398-2917AFBF-19FF-4FD8-AF98-D4AF2F64FBBFQ37148507-35E2AF24-658E-4D68-9F1E-9BA4850B37FEQ37199656-F70BDB56-B2C1-4DB0-BBBC-2BF8748E5FACQ37504141-6468513D-B822-4D5D-A165-0E06B2A000DEQ37564195-AB085168-89C9-4653-B822-40D10589E0B8Q37627065-E9EFBA1F-D71F-4587-BBD7-0066E99E474BQ37719047-6816C384-5EC5-4034-9407-DA7469EA6EFAQ38038399-46A965E9-08FD-4A23-A563-AB6D29D9A07AQ38067390-4F29AD3E-38B4-4DF3-B018-90607BCC0FBEQ38097197-4E4E10C5-554F-4553-BFE1-C1A05A9D985BQ38112617-8D2C33BF-26A3-494D-BC9A-4CF9F823D7B7
P2860
Reversal of fragile X phenotypes by manipulation of AβPP/Aβ levels in Fmr1KO mice
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Reversal of fragile X phenotypes by manipulation of AβPP/Aβ levels in Fmr1KO mice
@ast
Reversal of fragile X phenotypes by manipulation of AβPP/Aβ levels in Fmr1KO mice
@en
type
label
Reversal of fragile X phenotypes by manipulation of AβPP/Aβ levels in Fmr1KO mice
@ast
Reversal of fragile X phenotypes by manipulation of AβPP/Aβ levels in Fmr1KO mice
@en
prefLabel
Reversal of fragile X phenotypes by manipulation of AβPP/Aβ levels in Fmr1KO mice
@ast
Reversal of fragile X phenotypes by manipulation of AβPP/Aβ levels in Fmr1KO mice
@en
P2093
P2860
P1433
P1476
Reversal of fragile X phenotypes by manipulation of AβPP/Aβ levels in Fmr1KO mice
@en
P2093
Brian C Ray
Cara J Westmark
Crystal M Hervey
Elizabeth M Berry-Kravis
James S Malter
Kelsey M Stein
Levi A Stodola
M Shahriar Salamat
Michael Tranfaglia
Pamela R Westmark
P2860
P304
P356
10.1371/JOURNAL.PONE.0026549
P407
P577
2011-10-26T00:00:00Z